Drug Trial Radar · NCT03944772
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
247
Actual
Start
Jun 25, 2019
Primary completion
May 6, 2025
Study completion May 6, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Conditions
- Non-Small Cell Lung Cancer
Interventions
OsimertinibDrug
Osimertinib given orally at 80 mg once daily
SavolitinibDrug
Savolitinib will be given orally at 300 mg or 600mg once daily
GefitinibDrug
Gefitinib given orally at 250 mg once daily
NecitumumabDrug
Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
DurvalumabDrug
Durvalumab given IV at 1500 mg on Day 1 of every cycle
CarboplatinDrug
Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
PemetrexedDrug
Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
AlectinibDrug
Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
SelpercatinibDrug
Selpercatinib given orally at 160mg twice daily
SelumetinibDrug
Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
EtoposideDrug
Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
CisplatinDrug
Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
Datopotamab deruxtecanDrug
Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average
Locations
47 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Sacramento, California
Research Site
Santa Monica, California
Research Site
New Haven, Connecticut
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Grand Rapids, Michigan
Research Site
New York, New York
Research Site
New York, New York
Research Site
Portland, Oregon
Research Site
Pittsburgh, Pennsylvania
Research Site
Houston, Texas
Research Site
Seattle, Washington
Research Site
Odense C, Denmark
Research Site
Catania, Italy
Research Site
Naples, Italy
Research Site
Orbassano, Italy
Research Site
Padova, Italy
Research Site
Varese, Italy
Research Site
Chūōku, Japan
Research Site
Fukuoka, Japan
Research Site
Kōtoku, Japan
Research Site
Nagoya, Japan
Research Site
Osaka, Japan
Research Site
Wakayama, Japan
Research Site
Amsterdam, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Maastricht, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Drammen, Norway
Research Site
Oslo, Norway
Research Site
Trondheim, Norway
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.